|
Coronavirus lockdown benefits remain dubious as costs continue to mount
Featured on Fox News | Sally C. Pipes
September 8, 2020
The damage wrought by the draconian response to the pandemic doesn’t end there. The lockdowns have exerted a potentially life-threatening toll on the mental health of many Americans. A CDC report from last month found that one-quarter of adults ages 18 to 24 contemplated suicide in the previous month.
|
|
Dr. Henry Miller Quoted in Reuters Vaccine Article
Reuters | Michael Erman and Julie Steenhuysen
September 9, 2020
Dr. Henry Miller, a senior fellow at the Pacific Research Institute think tank and former director of the FDA’s office of biotechnology, said an emergency use authorization based on a small number of infections would not deliver an adequate answer on the safety of a vaccine intended for use by millions of healthy people. Some side effects could take four to six months to occur, he said.
Read more. . .
|
|
Pharmaceutical Companies Ruin Prospects for COVID-19 Vaccine “October Surprise”. That’s a Good Thing.
Featured in the Chicago Tribune and Real Clear Science | Henry Miller, M.S., M.D.
September 5, 2020
Well, the companies producing the leading coronavirus vaccine candidates have just effectively ruined the prospects for a pre-election “October Surprise” announcement of a vaccine approval. In an extraordinary move, several drug companies that are developing COVID-19 vaccines, including Johnson & Johnson, Pfizer, Moderna and Sanofi, are about to issue a statement pledging that they won’t seek government approval until their products have been proven to be safe and effective, and to adhere to the highest standards in clinical trials and manufacturing.
Read more. . .
|
|
COVID-19 Vaccines Must Be Fully Vetted For Safety And Efficacy Before Release
Issues & Insights | Henry Miller, M.S., M.D.
September 5, 2020
It was hardly a secret that there would be intense pressure on the FDA from a White House desperate for good news to provide an “October Surprise” in the form of a vaccine approval before the Nov. 3 election, even if that approval was premature. When I wrote about this subject for Issues & Insights a month ago, I described the wall that the head of the FDA, Dr. Stephen Hahn, and his colleagues had constructed in order to resist that pressure. Well, watch out for falling debris, because the wall is crumbling.
|
|
|
Watch the Latest "Escape the Drug Pricing Maze Video"
Making Biosimilars & Gene Therapies Affordable & Accessible: 3 Keys to Reform Drug Pricing System
As they approach the end of the Drug Pricing Maze, the Professor and Pete explore reforms to fix a broken system and encourage the use of cheaper biosimilars that can help patients and the health care system save big. They also learn what can be done to make very expensive gene therapies that provide a lot of value for patients more affordable and accessible.
|
|
|
|
